| Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript |
Call Start: 16:30 January 1, 0000 5:20 PM ET Inotiv, Inc. (NASDAQ:NOTV ) Q2 2025 Earnings Conference Call May 7, 2025, 04:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv Second Quarter Fiscal 2025 Earnings Call. [Operator Instructions] Please note, today's call will be recorded and I will be standing by should you need any assistance. |
seekingalpha.com |
2025-05-08 04:03:14 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates |
Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.29 per share a year ago. |
zacks.com |
2025-05-07 23:45:34 |
Czytaj oryginał (ang.) |
| Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update |
— Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million— Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million— Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2025”) ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025. |
globenewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release |
Inotiv (NOTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:18 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025 |
WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. |
globenewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. (NOTV) Q1 2025 Earnings Call Transcript |
Inotiv, Inc. (NASDAQ:NOTV ) Q1 2025 Results Conference Call February 5, 2025 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv First Quarter Fiscal 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-02-05 21:48:04 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025 |
WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. |
globenewswire.com |
2025-01-22 18:05:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million |
WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock on December 30, 2024. |
globenewswire.com |
2024-12-30 18:05:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million |
WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the initial 6,000,000 common shares on December 19, 2024. |
globenewswire.com |
2024-12-23 18:05:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. Launches Proposed Public Offering of Common Shares |
WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. |
globenewswire.com |
2024-12-17 18:03:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. (NOTV) Q4 2024 Earnings Call Transcript |
Inotiv, Inc. (NASDAQ:NOTV ) Q4 2024 Earnings Conference Call December 3, 2024 4:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Operator Good day, everyone, and welcome to today's Inotiv Fiscal 2024 Fourth Quarter Financial Results. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-12-03 20:22:05 |
Czytaj oryginał (ang.) |
| Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2024 and Provides Business Update |
— Enhanced liquidity through issuance of Second Lien Notes — Obtained amendment to credit agreement and extended note payable — Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million — Full year fiscal 2024 revenue down 14.3% to $490.7 million — Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2024”) and twelve months ("FY 2024") ended September 30, 2024. |
globenewswire.com |
2024-12-03 18:05:00 |
Czytaj oryginał (ang.) |
| Inotiv Ranked Number 138 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™ |
Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth |
globenewswire.com |
2024-11-21 10:30:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. to Report Fiscal 2024 Fourth Quarter and Full Year Results and Host Conference Call on Tuesday, December 3, 2024 |
WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on Tuesday, December 3, 2024, after the close of the stock market. |
globenewswire.com |
2024-11-20 18:05:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity |
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes due February 2027 (the “Second Lien Notes”), and warrants to purchase common shares, to certain investors in a private offering. |
globenewswire.com |
2024-09-16 12:00:00 |
Czytaj oryginał (ang.) |
| Inotiv to Participate in the 8th Annual Lake Street Best Ideas Growth Conference |
WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv's President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8th Annual Lake Street Best Ideas Growth Conference on Thursday, September 12, 2024, in New York City. |
globenewswire.com |
2024-08-28 20:05:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. (NOTV) Q3 2024 Earnings Call Transcript |
Inotiv, Inc. (NASDAQ:NOTV ) Q3 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Eric Coldwell - Baird Operator Good day, everyone and welcome to this Inotiv Third Quarter Earnings Conference Call. [Operator Instructions] And it's now my pleasure to turn the floor over to Mr. |
seekingalpha.com |
2024-08-09 02:55:28 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates |
Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.07 per share a year ago. |
zacks.com |
2024-08-08 23:15:59 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 |
WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8, 2024, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. |
globenewswire.com |
2024-07-25 12:00:00 |
Czytaj oryginał (ang.) |
| 3 Breakout Stocks to Buy Before They Make Headlines |
In the current volatile market, breakout stocks with sound growth potential are most important for those investors looking to maximize returns. The list includes three such standout companies that can deliver substantial gains. |
investorplace.com |
2024-07-09 10:50:00 |
Czytaj oryginał (ang.) |
| 3 Undervalued Stocks Primed for a 2X Return |
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan. |
investorplace.com |
2024-07-01 14:20:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. Provides Business Updates |
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates: |
globenewswire.com |
2024-06-10 11:30:00 |
Czytaj oryginał (ang.) |
| Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility |
Company reaffirms commitment to maintaining appropriate standards of animal welfare Company reaffirms commitment to maintaining appropriate standards of animal welfare |
globenewswire.com |
2024-06-03 17:24:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. to Participate in Upcoming Craig Hallum and Jefferies Investor Conferences |
WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the upcoming 21st Annual Craig Hallum Institutional Investor Conference and Jefferies Global Healthcare Conference. |
globenewswire.com |
2024-05-23 20:15:00 |
Czytaj oryginał (ang.) |
| Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Inotiv, Inc. (NOTV) |
NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Inotiv, Inc. (“Inotiv” or the “Company”) (NASDAQ: NOTV). The investigation concerns whether Inotiv and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On May 13, 2024, Inotiv disclosed that it is unable to timely file its Quarterly Report on Form 10-Q for the quarter e. |
businesswire.com |
2024-05-16 19:57:00 |
Czytaj oryginał (ang.) |
| Inotiv, Inc. (NOTV) Q2 2024 Earnings Call Transcript |
Inotiv, Inc. (NASDAQ:NOTV ) Q2 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Bob Yedid - Investor Relations Bob Leasure - President and CEO Beth Taylor - Chief Financial Officer Conference Call Participants Dave Windley - Jefferies Matt Hewitt - Craig-Hallum Frank Takkinen - Lake Street Capital Markets Operator Good afternoon ladies and gentlemen and welcome to the Inotiv's Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-16 02:05:25 |
Czytaj oryginał (ang.) |
| Inotiv Reports Second Quarter Financial Results for Fiscal 2024 and Provides Business Update |
— Second quarter fiscal 2024 revenue down 21.5% to $119.0 million— Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million— Agreement in principle reached with the U.S. Department of Justice on related matter— Site optimization projects near completion— Conference call begins today at 4:30 pm ET |
globenewswire.com |
2024-05-15 20:05:00 |
Czytaj oryginał (ang.) |